Cargando…

NK cell-based autologous immune enhancement therapy (AIET) for cancer

Natural killer (NK) cells have been known to enhance the host immune responses against cancer. NK cell number and cytotoxicity in patients with cancer is often low. Therefore, we developed a large-scale ex vivo NK cell expansion method without feeder layers and introduced NK cell-based autologous im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terunuma, H, Deng, X, Nishino, N, Watanabe, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of Stem Cells and Regenerative Medicine 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908307/ https://www.ncbi.nlm.nih.gov/pubmed/24693203

Ejemplares similares

Cell Based Autologous Immune Enhancement Therapy (AIET) after Radiotherapy in a Locally Advanced Carcinoma of the Cervix
por: Premkumar, Sumana, et al.
Publicado: (2013)

Evaluating the Safety and Quality of Life of Colorectal Cancer Patients Treated by Autologous Immune Enhancement Therapy (AIET) in Vinmec International Hospitals
por: Nguyen, Hoang-Phuong, et al.
Publicado: (2022)

Autologous immune enhancement therapy: A case report of a stage IV colonic cancer
por: SUBRAMANI, BASKAR, et al.
Publicado: (2013)

Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
por: Manjunath, Sadananda Rao, et al.
Publicado: (2012)

Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report
por: RATNAVELU, KANANATHAN, et al.
Publicado: (2013)

Harnessing NK Cells to Control Metastasis
por: Deng, Xuewen, et al.
Publicado: (2022)

Exploring the Utility of NK Cells in COVID-19
por: Deng, Xuewen, et al.
Publicado: (2022)

Immunosurveillance of Cancer and Viral Infections with Regard to Alterations of Human NK Cells Originating from Lifestyle and Aging
por: Deng, Xuewen, et al.
Publicado: (2021)

iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
por: Bogomiakova, Margarita E., et al.
Publicado: (2023)

The application of autologous cancer immunotherapies in the age of memory-NK cells
por: Lizana-Vasquez, Gaby D., et al.
Publicado: (2023)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
por: Mentlik James, Ashley, et al.
Publicado: (2013)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment
por: Orrantia, Ane, et al.
Publicado: (2021)

Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
por: Couto, Samuel C. F., et al.
Publicado: (2023)

Characterization of age-related immune features after autologous NK cell infusion: Protocol for an open-label and randomized controlled trial
por: Tang, Xiaofeng, et al.
Publicado: (2022)

Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells
por: Vahedi, Fatemeh, et al.
Publicado: (2017)

Variation in the manufacturing reproducibility of autologous cell-based products depending on raw material shipment conditions
por: Mizutani, Manabu, et al.
Publicado: (2019)

The role of NK cells in HIV-1 protection: autologous, allogeneic or both?
por: Hens, Jef, et al.
Publicado: (2016)

TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4(+) T cells
por: Holder, Kayla A, et al.
Publicado: (2021)

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
por: Sakamoto, Naoyuki, et al.
Publicado: (2015)

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy
por: Yano, Max, et al.
Publicado: (2022)

NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation
por: Jacobs, Benedikt, et al.
Publicado: (2015)

Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations
por: Hong, Guodai, et al.
Publicado: (2019)

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells
por: Buddingh, Emilie P., et al.
Publicado: (2011)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
por: Pesce, Silvia, et al.
Publicado: (2020)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma.
por: Balsari, A., et al.
Publicado: (1985)

NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies
por: Fregni, Giulia, et al.
Publicado: (2012)

Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells
por: Carrega, Paolo, et al.
Publicado: (2009)

NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma
por: Orrantia, Ane, et al.
Publicado: (2021)

Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy
por: Arnon, Tal I., et al.
Publicado: (2008)

Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
por: Shin, Eunju, et al.
Publicado: (2023)

P16. Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: a potential mechanism for the NK cell-based immunotherapy efficacy
por: Sconocchia, G, et al.
Publicado: (2014)

Exogenous activated NK cells enhance trafficking of endogenous NK cells to endometriotic lesions
por: Montenegro, Mary Lourdes, et al.
Publicado: (2015)

Autologous NK cells propagated and activated ex vivo decrease senescence markers in human PBMCs
por: Chelyapov, Nickolas, et al.
Publicado: (2022)

Combining Autologous Peripheral Blood Mononuclear Cells with Fibroblast Growth Factor Therapy Along with Stringent Infection Control Leading to Successful Limb Salvage in Diabetic Patient with Chronic Renal Failure and Severe Toe Gangrene
por: Osawa, Hiroshi, et al.
Publicado: (2014)

Antitumor effects of NK cells expanded by activation pre‑processing of autologous feeder cells before irradiation in colorectal cancer
por: Koh, Eun-Kyoung, et al.
Publicado: (2023)

Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy
por: Arnon, Tal I., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_531484na74h3bcc5qljs9vm12q